Presentations

OBRI Presentations from 2008 to 2023

Please note that prior to 2013, the OBRI was referred to as the Ontario Biologics Research Initiative.

International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Halifax, NS. 

Bhavsar S, Mohavedi M, Cesta A, Pope J, Bombardier C, and other OBRI investigators. Retention of triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine compared to combination methotrexate and leflunomide in rheumatoid arthritis. International Conference for Pharmacoepidemiology Conference. Halifax, Nova Scotia, August 23-27, 2023. Poster Presentation

Movahedi M, Cesta A, Li X, Bombardier C. Discontinuation and Effectiveness of Originator and Biosimilar TNFi in Patients with Rheumatoid Arthritis: Real World Data from a Rheumatoid Arthritis Registry in Canada. International Conference for Pharmacoepidemiology Conference. Halifax, Nova Scotia, August 23-27, 2023. Poster Presentation

Besette L,  Movahedi M, Choquette D, Coupal L, Bombardier C and other OBRI and RHUMADATA investigators. Impact of Antirheumatic Treatments on the Individual Components of the ACR Composite Score in Patients with Rheumatoid Arthritis. International Conference for Pharmacoepidemiology Conference. Halifax, Nova Scotia, August 23-27, 2023. Poster Presentation

Ontario Rheumatology Association Annual Scientific Meeting, Kingbridge Conference Centre, ON.  May 24-26, 2023 

Bhavsar S, Mohavedi M, Cesta A, Pope J, Bombardier C, and other OBRI investigators. Retention of triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine compared to combination methotrexate and leflunomide in rheumatoid arthritis.  Ontario Rheumatology Association Annual Scientific Meeting. Kingbridge Conference Centre, ON, May 24-26, 2024. Podium Poster

Movahedi M, Cui K, Cesta A, Li X, Bombardier C. Ontario Rheumatology Association Annual Scientific Meeting. Physical function and disease activity are affected by social determinants of health in patients with rheumatoid arthritis; Real world data from a Rheumatoid Arthritis Registry in Canada. Kingbridge Conference Centre, ON, May 24-26, 2024. Podium Poster

EULAR European Congress of Rheumatology, Milan, Italy, May 31-June 3, 2023.

Movahedi M, Cui K, Cesta A, Li X, Bombardier C. Physical function and disease activity are affected by social determinants of health in patients with rheumatoid arthritis; Real world data from a Rheumatoid Arthritis Registry in Canada.  EULAR Congress. Milan, Italy. May 31-June 3, Oral Presentation

Choquette D, Bombardier C, Cesta A, Coupal L, Keystone E, Li X, Movahedi M on behalf of OBRI and RHUMADATA investigators. What is the real-world effectiveness, safety profile, and persistence of Upadacitinib in real-world Canadian RA patients in mono and in combination with csDMARDs compared to biologic agents, in all lines of therapy.  EULAR Congress. Milan, Italy. May 31-June 3, Accepted for publication.

Movahedi M, Cesta A, Li X, Bombardier C.  Discontinuation and Effectiveness of Originator and Biosimilar TNFi in Patients with Rheumatoid Arthritis: Real World Data from a Rheumatoid Arthritis Registry in Canada. EULAR Congress. Milan, Italy.  May 31-June 3, Accepted for publication.

Canadian Rheumatology Association Annual Scientific Meeting, Quebec City, PQ, Feb 8-11, 2023. 

Bhavsar S, Mohavedi M, Cesta A, Pope J, Bombardier C, and other OBRI investigators. Retention of triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine compared to combination methotrexate and leflunomide in rheumatoid arthritis. Canadian Rheumatology Association Annual Scientific Meeting. Quebec City, PQ, Feb 8-11, 2023. Poster Tour

Li X, Cesta A, Movahedi M, Bombardier C. Late-onset rheumatoid arthritis has a similar time to remission as younger-onset rheumatoid arthritis. Canadian Rheumatology Association Annual Scientific Meeting. Quebec City, PQ, Feb 8-11, 2023. Poster Presentation

Choquette D, Bombardier C, Cesta A, Coupal L, Keystone  e, Li X, Movahedi M on behalf of OBRI and RHUMADATA investigators.  What is the real-world effectiveness, safety profile, and persistence of Upadacitinib in real-world Canadian RA patients in mono and in combination with csDMARDs compared to biologic agents, in all lines of therapy.  Canadian Rheumatology Association Annual Scientific Meeting. Quebec City, PQ, Feb 8-11, 2023. Poster Presentation

Aboulenain S, Li X, Movahedi M, Bombardier C, Kuriya B on behalf of OBRI Investigators.  Cardiovascular Risk and Advanced Therapies Retention in Rheumatoid Arthritis: Results from the OBRI. Canadian Rheumatology Association Annual Scientific Meeting. Quebec City, PQ, Feb 8-11, 2023. Poster Presentation

Wong-Pack M, Hepworth E, Movahedi M, Kuriya B, Pope J, Keystone E, Thorne C, Ahluwalia V, Cesta A, Mously C, Bombardier C, Lau A, Aydin SZ.  Impact of COVID-19 pandemic on patients with rheumatoid arthritis: Data from the Ontario Best Practices Research Initiative (OBRI). Canadian Rheumatology Association Annual Scientific Meeting. Quebec City, PQ, Feb 8-11, 2023. Poster Presentation

American College of Rheumatology (ACR) Convergence 2022, Philadelphia, Pennsylvania, November 10-14, 2022

Wong-Pack M, Hepworth E, Movahedi M, Kuriya B, Pope J, Keystone E, Thorne C, Ahluwalia V, Cesta A, Mously C, Bombardier C, Lau A, Aydin SZ. Impact of COVID-19 pandemic on patients with rheumatoid arthritis: Data from the Ontario Best Practices Research Initiative (OBRI). ACR Convergence, November 10–14, 2022. Poster Presentation

Li X, Cesta A, Movahedi M, Bombardier C. Late-onset rheumatoid arthritis has a similar time to remission as younger-onset rheumatoid arthritis. ACR Convergence, November 10–14, 2022. Poster Presentation

International Conference for Pharmacoepidemiology (ICPE) 2022

Matthew Wong-Pack, Elliot Hepworth, Mohammad Movahedi, Claire Bombardier, Arthur Lau, Sibel Aydin. Impact of COVID-19 pandemic on patients with rheumatoid arthritis: Data from the Ontario Best Practices Research Initiative (OBRI). Poster presentation at the International Conference for Pharmacoepidemiology.,  August 24-28, 2022, Copenhagen, Denmark.

CRA 2022

Movahedi, A. Cesta, X. Li, E. Keystone, C. Bombardier and OBRI investigators. Physician and Patient Reported Effectiveness Outcomes Are Similar in Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients: Results from The Ontario Best Practices Research Initiative (OBRI).  Poster tour abstract #TOUR07. Poster Tour presentation at the Canadian Rheumatology Association. February 8-11, 2022; virtual meeting.

Movahedi, A. Cesta, X. Li, E. Keystone, C. Bombardier and OBRI investigators. Discontinuation rate of Tofacitinib is similar when compared to TNF inhibitors in Rheumatoid Arthritis Patients: Results from The Ontario Best Practices Research Initiative (OBRI). Poster tour abstract #TOUR08. Poster Tour presentation at the Canadian Rheumatology Association. February 8-11, 2022; virtual meeting.

Mohammad Movahedi, Denis Choquette, Louis Coupal, Angela Cesta, Xiuying Li, Edward Keystone, Claire Bombardier on behalf of OBRI and RHUMADATA investigators Poster. Discontinuation Rate of Tofacitinib as Monotherapy is Similar Compared to Combination therapy with Methotrexate in Rheumatoid Arthritis Patients: Pooled Data from two Rheumatoid Arthritis Registries in Canada. Poster #112. Poster presentation at the Canadian Rheumatology Association. February 8-11, 2022; virtual meeting.

Guo, Xuiying Li, Mohammad Movahedi, Angela Cesta, Claire Bombardier on behalf of OBRI investigators. Biologics initiation in moderate vs severe rheumatoid arthritis patients: prospective observational study from a Canadian registry. Poster #113. Poster presentation at the Canadian Rheumatology Association. February 8-11, 2022; virtual meeting.

American College of Rheumatology (ACR) Convergence 2021, Virtual Meeting, November 5-9, 2021

Mohammad Movahedi, Denis Choquette, Louis Coupal, Angela Cesta, Xiuying Li, Edward Keystone, Claire Bombardier on behalf of OBRI and RHUMADATA investigators. Discontinuation Rate of Tofacitinib as Monotherapy is Similar Compared to Combination therapy with Methotrexate in Rheumatoid Arthritis Patients: Pooled Data from two Rheumatoid Arthritis Registries in Canada. Oral Presentation.

M. Movahedi, A. Cesta, X. Li, E. Keystone, C. Bombardier and OBRI investigators. Physician and Patient Reported Effectiveness Outcomes Are Similar in Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients: Results from The Ontario Best Practices Research Initiative (OBRI). Poster.

M. Movahedi, A. Cesta, X. Li, E. Keystone, C. Bombardier and OBRI investigators. Discontinuation rate of Tofacitinib is similar when compared to TNF inhibitors in Rheumatoid Arthritis Patients: Results from The Ontario Best Practices Research Initiative (OBRI). Poster.

Nancy Guo, Xuiying Li, Mohammad Movahedi, Angela Cesta, Claire Bombardier on behalf of OBRI investigators. Biologics initiation in moderate vs severe rheumatoid arthritis patients: prospective observational study from a Canadian registry. Poster.

EULAR 2021 Virtual Congress

Choquette, M. Movahedi, L. Coupal, A. Cesta, X. Li, E. Keystone, C. Bombardier on behalf of OBRI and RHUMADATA investigators. Discontinuation rate of Tofacitinib is similar when compared to TNF inhibitors in Rheumatoid Arthritis Patients: Pooled Data from two Rheumatoid Arthritis Registries in Canada. Abstract #OPO179 (page 107). Oral presentation at EULAR 2021 Virtual Congress. June 2-5, 2021.

Movahedi, A. Cesta, X. Li, E. Keystone, C. Bombardier and OBRI investigators. Physician and Patient Reported Effectiveness Outcomes Are Similar in Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients: Results from The Ontario Best Practices Research Initiative (OBRI).  Abstract #POS045 (page 452). Poster presentation at EULAR 2021 Virtual Congress. June 2-5, 2021.

Choquette, M. Movahedi, L. Coupal, A. Cesta, X. Li, E. Keystone, C. Bombardier on behalf of OBRI and RHUMADATA investigators. Discontinuation Rate of Tofacitinib as Monotherapy is Similar Compared to Combination therapy with Methotrexate in Rheumatoid Arthritis Patients: Pooled Data from two Rheumatoid Arthritis Registries in Canada.  Abstract#POS445 (page 454). Poster presentation at EULAR 2021 Virtual Congress. June 2-5, 2021.

N. Guo, X. Li, M. Movahedi, A. Cesta, C. Bombardier on behalf of OBRI investigators.  Biologics initiation in moderate vs severe rheumatoid arthritis patients: prospective observational study from a Canadian registry. Abstract #POS0449 (page 454). Poster presentation at EULAR 2021 Virtual Congress. June 2-5, 2021.

Canadian Arthritis Research Conference (CARC) 2021

Movahedi, A. Cesta, X. Li, E. Keystone, C. Bombardier and OBRI investigators. Physician and Patient Reported Effectiveness Outcomes Are Similar in Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients: Results from The Ontario Best Practices Research Initiative (OBRI). Poster presentation at Canadian Arthritis Research Conference (CARC). February 16-17, 2021; virtual meeting.

Choquette, M. Movahedi, L. Coupal, A. Cesta, X. Li, E. Keystone, C. Bombardier on behalf of OBRI and RHUMADATA investigators. Discontinuation Rate of Tofacitinib as Monotherapy is Similar Compared to Combination therapy with Methotrexate in Rheumatoid Arthritis Patients: Pooled Data from two Rheumatoid Arthritis Registries in Canada. Poster presentation at Canadian Arthritis Research Conference (CARC). February 16-17, 2021; virtual meeting.

D. Choquette, M. Movahedi, L. Coupal, A. Cesta, X. Li, E. Keystone, C. Bombardier on behalf of OBRI and RHUMADATA investigators.  Discontinuation rate of Tofacitinib is similar when compared to TNF inhibitors in Rheumatoid Arthritis Patients: Pooled Data from two Rheumatoid Arthritis Registries in Canada. Poster presentation at Canadian Arthritis Research Conference (CARC). February 16-17, 2021; virtual meeting.

CRA 2021

Keystone, M. Movahedi, A. Cesta, C. Bombardier, J. S. Sampalis, E. Rampakakis and OBRI investigators. Differential Influence of CDAI Components Based on Disease State in Rheumatoid Arthritis Patients: Real-World Results from A Rheumatoid Arthritis Cohort. Poster presentation at Canadian Rheumatology Association. February 24-26, 2021; virtual meeting.

Movahedi, A. Cesta, X. Li, E. Keystone, C. Bombardier and OBRI Investigators. Disease Activity Trajectories for Early and Established Rheumatoid Arthritis: Real-World Results from A Rheumatoid Arthritis Cohort. Poster presentation at Canadian Rheumatology Association. February 24-26, 2021; virtual meeting.

Movahedi, A. Cesta, X Li, C Bombardier and OBRI investigators. Sociodemographic, disease, and medication profile of RA patients under 65 years old compared with patients with 65 or older at registry enrolment: Real-World Results from A Rheumatoid Arthritis Cohort. Poster presentation at Canadian Rheumatology Association. February 24-26, 2021; virtual meeting.

Thorne, E. Keystone, P. Ciaschini, V. Ahluwalia, A. Lau, J. Brophy, V. Pavlova, G. Major, E. Rampakakis, X. Li, A. Cesta, M. Movahedi, C. Mously, C. Bombardier. Medical Cannabis Use in Patients Attending Rheumatology Clinics in Ontario. Poster presentation at Canadian Rheumatology Association. February 24-26, 2021; virtual meeting.

Movahedi, A. Cesta, X. Li, E. Keystone, C. Bombardier and OBRI Investigators. Discontinuation rate of Tofacitinib is similar when compared to TNF inhibitors in Rheumatoid Arthritis Patients: Real-World Results from A Rheumatoid Arthritis Cohort. Poster presentation at Canadian Rheumatology Association. February 24-26, 2021; virtual meeting.

G. Hazlewood, C. Bombardier, X. Li, M. Movahedi, D. Choquette, L. Coupal, V. Bykerk, O. Schieir, D. Mosher, D. Marshall, S. Bernatsky, N. Spencer, C. Barber, on behalf of OBRI, RHUMADATA®, CATCH and The Rheum4U Team. Patient Characteristics and Treatment Patterns Across Four Canadian Rheumatoid Arthritis Cohorts. Poster presentation at Canadian Rheumatology Association. February 24-26, 2021; virtual meeting.

E. Hepworth, R. Mirza, M. Movahedi, S. Ayden, A. Cesta, C. Bombardier, and OBRI investigators.  Comparing Academic and Community Practices in the Management of Rheumatoid Arthritis: Data from the OBRI Registry. Poster presentation at Canadian Rheumatology Association. February 24-26, 2021; virtual meeting.

Pope, J, Hall S, Bombardier C, Keystone E, Haroui B, Jones G, Naik L, Etzel C, Infante R, Wu D.  Effectiveness after Transition to SB4 (brenzys, Etanercept (ETN) Originator (Enbrel) Among Rheumatoid Arthritis (RA) Patients in Low Disease Activity:  A Prospective Multinational Multicenter Observational Study (COMPANION B).  Canadian Rheumatology Association Meeting Virtual Congress February 24 – 26, 2021, Poster #94. J Rheumatol 2021 Jul;48(7):1155. Epub 2021 May 15.  PMID: 33993118 DOI: 10.3899/jrheum.210406

American College of Rheumatology (ACR) Convergence 2020, Virtual Meeting. 

Edward Keystone, Mohammad Movahedi, Angela Cesta, Claire Bombardier, John S. Sampalis, Emmanouil Rampakakis. Differential Influence of CDAI Components Based on Disease State in Rheumatoid Arthritis Patients_Real World Results from a Rheumatoid Arthritis Cohort.  ACR 2020, Virtual Meeting. November 5-9, 2020. (Oral Presentation)

Mohammad Movahedi, Angela Cesta, Xiuying Li, Edward Keystone, Claire Bombardier and OBRI investigators.  Discontinuation rate of Tofacitinib is similar when compared to TNF inhibitors in Rheumatoid Arthritis Patients_Real World Results from a Rheumatoid Arthritis Cohort.  ACR 2020, Virtual Meeting. November 5-9, 2020. (Poster Presentation)

Mohammad Movahedi, Angela Cesta, Xiuying Li, Edward Keystone, Claire Bombardier and OBRI investigators. Time to Discontinuation of Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients with and Without Methotrexate_Real World Results from a Rheumatoid Arthritis Cohort. ACR 2020, Virtual Meeting. November 5-9, 2020. (Poster Presentation)

Mohammad Movahedi, Angela Cesta, Xiuying Li, Claire Bombardier and other OBRI investigators. Disease activity trajectories for early and established rheumatoid arthritis_data from a rheumatoid arthritis cohort.  ACR 2020, Virtual Meeting. November 5-9, 2020. (Poster Presentation)

Mohammad Movahedi, Angela Cesta, Xiuying Li, Claire Bombardier and OBRI investigators.  Sociodemographic, disease, and medication profile of RA patients under 65 years compared with 65years or older at registry enrollment.  ACR 2020, Virtual Meeting. November 5-9, 2020. (Poster Presentation)

Canadian Association for Population Therapeutics (CAPT) 2020, Virtual Meeting

E. Hepworth, R. Mirza, M. Movahedi, A. Cesta, C. Bombardier and OBRI investigators.  Comparing academic and community practices in the management of rheumatoid arthritis_data from the OBRI registry. CAPT 2020 Annual Conference, Toronto, ON. Oct 26-27. (Oral Presentation)

Movahedi, A. Cesta, X Li, C Bombardier and OBRI investigators.  Sociodemographic, disease, and medication profile of RA patients under 65 years compared with 65years or older at registry enrollment.  CAPT 2020 Annual Conference, Toronto, ON. Oct 26-27. (Oral Presentation)

Movahedi, A. Cesta, X. Li, E. Keystone, C. Bombardier and OBRI Investigators. Disease activity trajectories for early and established rheumatoid arthritis_data from a rheumatoid arthritis cohort.  CAPT 2020 Annual Conference, Toronto, ON. Oct 26-27. (Poster Presentation)

CRA 2020

Eraso M, Cesta A, Yang Ye, Mohavedi M, Thorne C, Ahluwalia V, Karasik A, Chow A, Averns H, Khan I, Bensen W, Rai R, Dixit S, Mulgund M, Ciaschini P, Lau A, Haaland D, Inman RD, Haroon N, Gladman DD, Bombardier C, Chandran V.  Comparison between Patients with Spondyloarthritis Managed in Community Based Care Settings to those Managed in Tertiary Research Setting in Ontario: An OBRI-SPARCC Study. CRA Annual Meeting, Victoria, BC. February 26-29, 2020. (Poster Presentation)

Mohammad Movahedi, A. Cesta, X. Li, C. Bombardier on behalf of Other OBRI Investigators.  Time to Discontinuation of Tofacitinib and TNF inhibitors in Rheumatoid Arthritis Patients with and without Methotrexate: Data from A Rheumatoid Arthritis Cohort.  CRA Annual Meeting, Victoria, BC. February 26-29, 2020. (Poster Presentation)

Janet Pope, Emmanouil Rampakakis, Mohammad Movahedi, Angela Cesta, John S. Sampalis, Claire Bombardier and OBRI investigators.  Does Improvement in Patient Pain and Fatigue Lag Behind Clinical Remission in Rheumatoid Arthritis Patients? Data from a Rheumatoid Arthritis Registry. CRA Annual Meeting, Victoria, BC. February 26-29, 2020. (Poster Presentation)

Janet Pope, E. Rampakakis, M. Movahedi, A. Cesta, J. S. Sampalis, C. Bombardier and OBRI Investigators.  Differences Between Early and Established Rheumatoid Arthritis in Time to Achieving CDAI but not Fatigue Low Disease Activity and Remission: Data from the OBRI Registry.  CRA Annual Meeting, Victoria, BC. February 26-29, 2020. (Poster Presentation)

Thorne, A. Cesta, M. Mohavedi, V. Ahluwalia, V. Chandran, E. Keystone, A. Lau, J. Pope, E. Rampakakis, C. Bombardier. Rheumatologist Survey on Medical Cannabis: Results from the Ontario Best Practices Research Initiative (OBRI). CRA Annual Meeting, Victoria, BC. February 26-29, 2020. (Poster Presentation)

ACR 2019

Pope Janet, Rampakakis Emmanouil, Movahedi Mohammad, Cesta Angela, Sampalis John and Bombardier Claire.  Does Improvement in Patient Pain and Fatigue Lag Behind Clinical Remission in Rheumatoid Arthritis Patients? Data from a Rheumatoid Arthritis Registry.  American College of Rheumatology Annual Meeting, Atlanta, GA, USA. November 8-13, 2019 (Poster Presentation)

Movahedi Mohammad, Cesta Angela, Li Xiuying, Keystone Edward, Bombardier Claire and Other OBRI Investigators.  Time to Discontinuation of Tofacitinib in Rheumatoid Arthritis Patients with and Without Methotrexate: Results from a Rheumatoid Arthritis Cohort.  American College of Rheumatology Annual Meeting, Atlanta, GA, USA. November 8-13, 2019 (Poster Presentation)

EULAR 2019

Kangping Cui, Mohammad Movahedi, Claire Bombardier, Bindee Kuriya, and OBRI Investigators. Development of an Algorithm for the Classification of Cardiovascular Comorbidities in a large Rheumatoid Arthritis Registry: Data from the Ontario Best Practices Research Initiative. EULAR Annual Scientific Meeting, Madrid, ESP. June 12-15, 2019 (ACCEPTED, Poster Presentation)

Kangping Cui, Mohammad Movahedi, Claire Bombardier, Bindee Kuriya, and OBRI Investigators. Cardiovascular Disease Risk Factors May Negatively Impact Rheumatoid Arthritis Disease Outcomes: Findings from the Ontario Best Practices Research Initiative. EULAR Annual Scientific Meeting, Madrid, ESP. June 12-15, 2019 (ACCEPTED, Poster Presentation)

Elliot Hepworth, Mohammad Movahedi, Emmanouil Rampakakis, Reza Mirza, Arthur Lau, Angela Cesta, Janet Pope, John. S. Sampalis, Claire Bombardier and OBRI investigators. A Descriptive Analysis of Longitudinal Changes in Relative Market Share Proportions of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs For Treatment of Rheumatoid Arthritis: Data From the OBRI Database.  EULAR Annual Scientific Meeting, Madrid, ESP. June 12-15, 2019 (ACCEPTED, Poster Presentation)

Poohen Akhavan, Mohammad Movahedi, Claire Bombardier. Factors affecting the discrepancy between patient and physician global assessment of disease activity in patients with early rheumatoid arthritis over time. EULAR Annual Scientific Meeting, Madrid, ESP. June 12-15, 2019 (ACCEPTED, Poster Presentation)

M. Movahedi, A. Cesta, X. Li, C. Bombardier on behalf of Other OBRI Investigators. Time to discontinuation of Tofacitinib in patients with rheumatoid arthritis with and without methotrexate: results from the Ontario Best Practices Research Initiative (OBRI). EULAR Annual Scientific Meeting, Madrid, ESP. June 12-15, 2019

CRA 2019

Kangping Cui, Mohammad Movahedi, Claire Bombardier, Bindee Kuriya, and OBRI Investigators. Development of an Algorithm for the Classification of Cardiovascular Comorbidities in a large Rheumatoid Arthritis Registry: Data from the Ontario Best Practices Research Initiative. CRA Annual Meeting, Montreal, PQ. February 27-March 2, 2019 (Poster Presentation)

Kangping Cui, Mohammad Movahedi, Claire Bombardier, Bindee Kuriya, and OBRI Investigators. Cardiovascular Disease Risk Factors May Negatively Impact Rheumatoid Arthritis Disease Outcomes: Findings from the Ontario Best Practices Research Initiative. CRA Annual Meeting, Montreal, PQ. February 27-March 2, 2019 (Poster Presentation)

Elliot Hepworth, Mohammad Movahedi, Emmanouil Rampakakis, Reza Mirza, Arthur Lau, Angela Cesta, Janet Pope, John. S. Sampalis, Claire Bombardier and OBRI investigators.  A Descriptive Analysis of Longitudinal Changes in Relative Market Share Proportions of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs For Treatment of Rheumatoid Arthritis: Data From the OBRI Database. CRA Annual Meeting, Montreal, PQ. February 27-March 2, 2019 (Poster Presentation)

ACR 2018

Kangping Cui, Mohammad Movahedi, Claire Bombardier, Bindee Kuriya, and OBRI Investigators. Development of an Algorithm for the Classification of Cardiovascular Comorbidities in a large Rheumatoid Arthritis Registry: Data from the Ontario Best Practices Research Initiative. ACR Annual Scientific Meeting, Chicago, IL. October 19-2, 2018 (Poster Presentation)

Kangping Cui, Mohammad Movahedi, Claire Bombardier, Bindee Kuriya, and OBRI Investigators. Cardiovascular Disease Risk Factors May Negatively Impact Rheumatoid Arthritis Disease Outcomes: Findings from the Ontario Best Practices Research Initiative. ACR Annual Scientific Meeting, Chicago, IL. October 19-2, 2018 (Poster Presentation)

Mohammad Movahedi, Elliot Hepworth, Reza Mirza, Angela Cesta, Maggie Larche, Claire Bombardier and OBRI investigators. Time to Discontinuation of Biologic Therapy by Mechanism of Action in Rheumatoid Arthritis: Results from The Ontario Best Practice Research Initiative (OBRI) Cohort. ACR Annual Scientific Meeting, Chicago, IL. October 19-2, 2018 (Poster Presentation)

Elliot Hepworth, Mohammad Movahedi, Emmanouil Rampakakis, Reza Mirza, Arthur Lau, Angela Cesta, Janet Pope, John. S. Sampalis, Claire Bombardier and OBRI investigators.  A Descriptive Analysis of Longitudinal Changes in Relative Market Share Proportions of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs For Treatment of Rheumatoid Arthritis: Data From the OBRI Database. ACR Annual Scientific Meeting, Chicago, IL. October 19-2, 2018 (Poster Presentation)

EULAR 2018

Pope, J.,  Movahedi, M., Rampakakis, E., Cesta, A., Sampalis, J.S., Bombardier, C., and OBRI Investigators.  Anti-CCP and Rheumatoid Factor as Predictors of Sustained Clinical Remission in Rheumatoid Arthritis Patients: Data from a Canadian Observational Cohort.  EULAR Annual Scientific Meeting.  Amsterdam, NL, June 13-17, 2018. (Guided Poster Tour)

Joshi, R., Movahedi, M., Rampakakis, E., Thorne, C., Cesta, A., Sampalis, J.S., Bombardier, C., and OBRI Investigators.  Impact of Residential Area on the Profile of Rheumatoid Arthritis Patients Initiating their First Biologic DMARD: Results from the Ontario Best Practices Research Initiative (OBRI).  EULAR Annual Scientific Meeting. Amsterdam, NL, June 13-17, 2018. (Poster Presentation)

Movahedi, M., Couto, S., Cesta, A., Bombardier, C., and OBRI Investigators.  Time to Discontinuation of Biologic Therapy by Mechanism of Action in Rheumatoid Arthritis: Results from the Ontario Best Practice Research Initiative (OBRI) Cohort.  EULAR Annual Scientific Meeting. Amsterdam, NL, June 13-17, 2018. (Poster Presentation)

Movahedi, M., Cesta, A., Li, X., Bombardier, C., and OBRI investigators.  Collection of Anti-Rheumatic Medication Data from Both Patients and Rheumatologists Shows Strong Agreement in a Real World Clinical Cohort:  The Ontario Best Practices Research Initiative (OBRI) a Rheumatoid Arthritis Cohort. EULAR Annual Scientific Meeting. Amsterdam, NL, June 13-17, 2018. (Poster Presentation)

CRA 2018

Joshi, R., Movahedi, M., Rampakakis, E., Cesta, A., Sampalis, J.S., Bombardier, C., and OBRI Investigators.  Impact of Residential Area on the Profile of Rheumatoid Arthritis Patients Initiating their First Biologic DMARD: Results from the Ontario Best Practices Research Initiative (OBRI).  CRA Annual Scientific Meeting.  Vancouver, BC, February 21-24, 2018. (Poster Presentation)

Li, X., Cesta, A., Movahedi, M., Bombardier, C., and OBRI Investigators. Clinical Response to the First Biologic in Rheumatoid Arthritis Patients with Moderate Disease in a Real World Clinical Cohort.   CRA Annual Scientific Meeting.  Vancouver, BC, February 21-24, 2018. (Poster Presentation)

Movahedi, M., Couto, S., Cesta, A., Bombardier, C., and OBRI Investigators.  Time to Discontinuation of Biologic Therapy by Mechanism of Action in Rheumatoid Arthritis: Results from the Ontario Best Practice Research Initiative (OBRI) Cohort.  CRA Annual Scientific Meeting.  Vancouver, BC, February 21-24, 2018. (Poster Presentation)

Pope, J., Rampakakis, E., Movahedi, M., Cesta, A., Sampalis, J.S., Bombardier, C., and OBRI Investigators.  Anti-CCP and Rheumatoid Factor as Predictors of Sustained Clinical Remission in Rheumatoid Arthritis Patients: Data from a Canadian Observational Cohort.  CRA Annual Scientific Meeting.  Vancouver, BC, February 21-24, 2018. (Poster Presentation)

ACR 2017

Joshi, R., Movahedi, M., Rampakakis, E., Cesta, A., Li, X., Couto, S., Sampalis, J.S., Bombardier, C., Kuriya, B., and OBRI Investigators.  High disease activity is a predictor of depression and persistent depression in early rheumatoid arthritis: results from the Ontario Best Practices Research Initiative (OBRI).  ACR Annual Scientific Meeting, San Diego, CA. November 3-8, 2017. (Oral Presentation)

Li, X., Cesta, A., Movahedi, M., Bombardier, C., and OBRI investigators. Clinical Response to the First Biologic in Rheumatoid Arthritis Patients with Moderate Disease in a Real World Clinical Cohort. ACR Annual Scientific Meeting, San Diego, CA. November 3-8, 2017. (Poster Presentation)

Movahedi, M., Cesta, A., Li, X., Bombardier, C., and OBRI investigators.  Collection of Anti-Rheumatic Medication Data from Both Patients and Rheumatologists Shows Strong Agreement in a Real World Clinical Cohort:  The Ontario Best Practices Research Initiative (OBRI) a Rheumatoid Arthritis Cohort. ACR Annual Scientific Meeting, San Diego, CA. November 3-8, 2017. (Poster Presentation)

Pope, J., Rampakakis, E., Movahedi, E., Cesta, A., Sampalis, J.S., Bombardier, C., and OBRI Investigators.  Anti-CCP and Rheumatoid Factor as Predictors of Sustained Clinical Remission in Rheumatoid Arthritis Patients: Data from a Canadian Observational Cohort. ACR Annual Scientific Meeting, San Diego, CA. November 3-8, 2017. (Poster Presentation)

Li, G., Li, X., Lau, A., Bombardier, C., and Adachi, J.D.  Frailty and Risk of Fractures in Patients with Rheumatoid Arthritis: Data from the Ontario Biologics Research Initiative.  ACR Annual Scientific Meeting, San Diego, CA. November 3-8, 2017. (Poster Presentation)

EULAR 2017

Ahluwalia, V., Movahedi, M., Rampakakis, E., Cesta, A., Li, X., Couto, S., Sampalis, J.S., Bombardier, C., and OBRI Investigators. Predictors of patient reported decision to discontinue Anti-Rheumatic Medication in Rheumatoid Arthritis Patients: Data from a Rheumatoid Arthritis Cohort.  EULAR Annual Scientific Meeting, Madrid, Spain. June 14-17, 2017. (Oral Presentation)

Joshi, R., Kuriya, B., Movahedi, M., Rampakakis, E., Cesta, A., Li, X., Couto, S., Sampalis, J.S., Bombardier, C., and OBRI Investigators. High disease activity is a predictor of depression and persistent depression in early rheumatoid arthritis: results from the Ontario Best Practices Research Initiative (OBRI). EULAR Annual Scientific Meeting, Madrid, Spain. June 14-17, 2017. (Poster Presentation)

CRA 2017

Couto, S., Cesta, A., Ahluwalia, V., Haaland, D., Karasik, A., Sebaldt, R., Thorne, C., Bombardier, C. Automated Data Extraction from Electronic Medical Records in Rheumatology – An Ontario Best Practices Research Initiative Pilot Project. CRA Annual Scientific Meeting, Ottawa, ON. February 8-11, 2017. (Poster Presentation)

Movahedi, M., Cesta, A., Li, X., Bombardier, C., and OBRI Investigators. Collection of Anti-Rheumatic Medication Data From Both Patients and Rheumatologists Shows Strong Agreement in a Real World Clinical Cohort (OBRI). CRA Annual Scientific Meeting, Ottawa, ON. February 8-11, 2017. (Poster Presentation)

Joshi, R., Kuriya, B., Movahedi,  M., Rampakakis, E., Cesta, A., Li, Couto, S., Sampalis, J.S., Bombardier, C., and OBRI Investigators. High disease activity is a predictor of depression and persistent depression in early rheumatoid arthritis – results from the Ontario Best Practices Research Initiative (OBRI).  CRA Annual Scientific Meeting, Ottawa, ON. February 8-11, 2017. (Poster Presentation)

Lau, A., Thorne, C., Movahedi, M., Cesta, A., Li, X., Couto, S., Sampalis, J.S., Rampakakis, E., Bombardier, C., and OBRI investigators.  Impact of Concomitant Use of Disease Modifying Antirheumatic Drugs and Methotrexate Administration Route on Durability of Biologic Treatment – Results from the Ontario Best Practice Research Initiative (OBRI) Cohort.  CRA Annual Scientific Meeting, Ottawa, ON. February 8-11, 2017. (Poster Presentation)

Tatangelo, M., Li, X., Cesta, A., Movahedi, M., Bombardier, C., Tomlinson, G.  Multiple Statistical Imputation of Missing Data in a Real World Clinical Cohort Increased Sample Size and Power with Minimal Deviations Enhancing the Clinical Research Potential of the Observational Dataset.  CRA Annual Scientific Meeting, Ottawa, ON. February 8-11, 2017. (Poster Presentation)

Fullerton, L., Brooks, S., Sweezie, R., Ahluwalia, V., Bombardier, C., Gagliardi, A.R. Patient, Rheumatologist, and Extended Role Practitioner (ERP) Perspectives on the Implementation and Impact of an Allied Health Rheumatology Triage Initiative in Ontario Rheumatology Clinics.  CRA Annual Scientific Meeting, Ottawa, ON. February 8-11, 2017. (Poster Presentation)

Brooks, S., Bombardier, C., Bell, M., Cesta, A., Fullerton, L., Karasik, A., Kendzerska, T., Sweezie, R., Widdifield, J., Ahluwalia, V. The Effect of Triage Assessments on Identifying Inflammatory Arthritis and Reducing Rheumatology Wait Times in Ontario.  CRA Annual Scientific Meeting, Ottawa, ON. February 8-11, 2017. (Poster Presentation)

Ahluwalia, V., Movahedi, M., Rampakakis, E., Cesta, A., Li, X., Couto, S., Sampalis, J.S., Bombardier, C., and OBRI investigators. Predictors of patient reported decision to discontinue Anti-Rheumatic Medication in Rheumatoid Arthritis Patients – Data from a Rheumatoid Arthritis Cohort  CRA Annual Scientific Meeting, Ottawa, ON. February 8-11, 2017. (Poster Presentation)

ACR 2016:

Ahluwalia V, Movahedi M, Rampakakis E, Cesta A, Li X, Sampalis J, Bombardier C, OBRI Investigators. Predictors of Non-Adherence with Anti-Rheumatic Medication in Rheumatoid Arthritis Patients: Results from the Ontario Best Practices Research Initiative. ACR Annual Scientific Meeting, Washington DC. Nov. 15, 2016. (Oral Presentation)

Thorne C, Movahedi M, Cesta A, Li X, Couto S, Rampakakis E, Sampalis J, Bombardier C. Concomitant Use of Oral vs. Subcutaneous Methotrexate at Biologic Initiation: a Comparison of Biologic Treatment Survival in the Ontario Best Practice Research Initiative (OBRI) Cohort. ACR Annual Scientific Meeting, Washington, DC. Nov. 15, 2016. (Poster Presentation)

Brooks S, Bombardier C, Bell M, Cesta A, Kendzerska,T, Sweezie R, Widdifield J, Fullerton L, Ahluwalia V, Karasik A. The Effect of Triage Assessments on Identifying Inflammatory Arthritis and Reducing Rheumatology Wait Times in Ontario. ACR Annual Scientific Meeting, Washington DC. Nov. 15, 2016. (Poster Presentation)

EULAR 2016:

Cesta A, Li X, Tatangelo M, Bombardier C, and OBRI Investigators. Attrition and Participant Characteristics in a Rheumatoid Arthritis Cohort. EULAR Annual Scientific Meeting. London, UK. June 8-11th, 2016.

Lau A, Movahedi M, Tatangelo M, Bombardier C and OBRI Investigators. Persistence with Biologic Monotherapy in Comparison with Combination Therapy with Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis; Results from a Rheumatoid Arthritis Cohort. EULAR Annual Scientific Meeting. London, UK. June 8-11th, 2016.

Cui K, Bombardier C, Tomlinson GA, and OBRI Investigators. Contributions of Social Determinants of Health on Remission in Rheumatoid Arthritis. EULAR Annual Scientific Meeting. London, UK. June 8-11th, 2016.

Pope JE, Movahedi M, Cesta A, Li X, Couto S, Rampakakis E, Sampalis JS, Bombardier C. and OBRI Investigators. Treatment Patterns in Rheumatoid Arthritis after Methotrexate: Data from an Ontario Rheumatoid Arthritis Cohort. EULAR Annual Scientific Meeting. EULAR Annual Scientific Meeting. London, UK. June 8-11th, 2016. (Supplementary Publication)

Roehkar G, Movahedi M, Pope JE, Bombardier C. Durability of First Biologic is Not Influenced by Initial/Early DAS28. EULAR Annual Scientific Meeting. London, UK. June 8-11th, 2016. (Supplementary Publication)

CRA 2016:

Lau A, Movahedi M, Tatangelo M, Bombardier C and OBRI Investigators. Persistence with Biologic Monotherapy in Comparison with Combination Therapy with Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis; Results from a Rheumatoid Arthritis Cohort. CRA Annual Scientific Meeting. Lake Louise, AB, Feb 17-20th, 2016.

Pope JE, Movahedi M, Cesta A, Li X, Couto S, Rampakakis E, Sampalis JS, Bombardier C and OBRI investigators. Treatment Patterns in Rheumatoid Arthritis after Methotrexate: Data from an Ontario Rheumatoid Arthritis Cohort. CRA Annual Scientific Meeting. Lake Louise, AB, Feb 17-20th, 2016.

Thorne C, Movahedi M, Cesta A, Li X, Couto S, Rampakakis E, Sampalis J, Bombardier C. Concomitant Use of Oral vs. Subcutaneous Methotrexate at Biologic Initiation:  a Comparison of Biologic Treatment Survival in the Ontario Best Practice Research Initiative (OBRI) Cohort. CRA Annual Scientific Meeting. Lake Louise, AB, Feb 17-20th, 2016.

Keystone E, Movahedi M, Cesta A, Li X, Couto S, Rampakakis E, Sampalis JS, Bombardier C and OBRI Investigators. What is the Rate of Primary and Secondary Failure of Anti-TNF in RA Patients? An Analysis from a Prospective, Observational Registry. CRA Annual Scientific Meeting. Lake Louise, AB, Feb 17-20th, 2016.

Tatangelo M, Paterson M, Tomlinson GA, Bansback N, Widdifield J, Gomes T, Bombardier C. Temporal Trends in Drug Prescription, Utilization and Costs Among Rheumatoid Arthritis (RA) Patients Show Wide Regional Variation Despite Universal Drug Coverage. CRA Annual Scientific Meeting. Lake Louise, AB, Feb 17-20th, 2016.

Cui K, Bombardier C, Tomlinson GA, and OBRI Investigators. Contributions of Social Determinants of Health on Treatment Responses in Rheumatoid Arthritis Patients. CRA Annual Scientific Meeting. Lake Louise, AB, Feb 17-20th, 2016.

Kuriya B, Li X, Tomlinson GA, Keystone E, Bombardier C, and OBRI Investigators. Predictors of Disease Relapse and Recapture of Remission Following Relapse in an Ontario Rheumatoid Arthritis Population. CRA Annual Scientific Meeting. Lake Louise, AB, Feb 17-20th, 2016.

Cesta A, Li X, Tatangelo M, Bombardier C and OBRI Investigators. Attrition and Participant Characteristics in a Rheumatoid Arthritis Cohort. CRA Annual Scientific Meeting. Lake Louise, AB, Feb 17-20th, 2016.

ACR 2015:

Lau A, Movahedi M, Tatangelo M, Bombardier C, and OBRI Investigators. Persistence with Biologic Monotherapy in Comparison with Combination Therapy with Disease-Modifying  Antirheumatic Drugs in Patients with Rheumatoid Arthritis; Results from a Rheumatoid Arthritis Cohort. ACR Annual Scientific Meeting, San Francisco, CA, Nov 7-11th, 2015. (Poster Presentation)

Pope JE, Movahedi M, Cesta A, Li X, Couto S, Rampakakis E, Sampalis JS, Bombardier C, and OBRI investigators. Treatment patterns in rheumatoid arthritis after methotrexate:  Data from an Ontario Rheumatoid Arthritis Cohort. ACR Annual Scientific Meeting, San Francisco, CA, Nov 7-11th, 2015. (Poster Presentation)

Tatangelo M, Paterson M, Tomlinson GA, Bansback N, Widdifield J, Gomes T, Bombardier C. Temporal trends in drug prescription, utilization and costs among Rheumatoid Arthritis (RA) patients show wide regional variation despite universal drug coverage. ACR Annual Scientific Meeting, San Francisco, CA, Nov 7-11th, 2015. (Oral Presentation)

Tatangelo M, Tomlinson GA, Kuriya B, Bombardier C. Disease Activity Patterns in Incident Onset Rheumatoid Arthritis Patients in the First 3-Years of Follow up. ACR Annual Scientific Meeting, San Francisco, CA, Nov 7-11th, 2015. (Poster Presentation)

Cui K, Bombardier C, Tomlinson GA, and the OBRI Investigators. Contributions of social determinants of health on treatment responses in Rheumatoid Arthritis patients. ACR Annual Scientific Meeting, San Francisco, CA, Nov 7-11th, 2015. (Poster Presentation)

Kuriya B, Li X, Tomlinson GA, Keystone EC, Bombardier C, and OBRI Investigators. Predictors of disease relapse and recapture of remission following relapse in an Ontario rheumatoid arthritis population. ACR Annual Scientific Meeting, San Francisco, CA, Nov 7-11th, 2015. (Oral Presentation)

Kelkar A, Cesta A, Li X, Bombardier C, and the OBRI Investigators. Characterization of patient reported pain medication in early Vs. established Rheumatoid Arthritis. ACR Annual Scientific Meeting, San Francisco, CA, Nov 7-11th, 2015. (Poster Presentation)

Keystone E, Movahedi M, Cesta A, Li X, Couto S, Rampakakis E, Sampalis JS, Bombardier C, OBRI Investigators. What is the rate of primary and secondary failure of anti-TNF in RA patients? An analysis from a prospective, observational registry. ACR Annual Scientific Meeting, San Francisco, CA, Nov 7-11th, 2015. (Poster Presentation)

Fullerton L., Cesta A., Hofstetter C., Bombardier C.  and the OBRI Investigators. Patient priorities in RA research: An exploration of perspectives from those enrolled in a Canadian RA clinical cohort. ACR Annual Scientific Meeting, San Francisco, CA, Nov 7-11th, 2015. (Poster Presentation)

Cesta A, Li X, Tatangelo M, Bombardier C, and  the OBRI Investigators. Attrition and participant characteristics in a Rheumatoid Arthritis cohort. ACR Annual Scientific Meeting, San Francisco, CA, Nov 7-11th, 2015. (Poster Presentation)

EULAR 2015:

Cui K, Jacob B, Widdifield J, Pope J, Kuriya B, Akhavan P, Bombardier C. Characteristics of rheumatoid arthritis patient with and without cardiovascular disease – Data from the Ontario Best Practices Research Initiative. EULAR Annual Scientific Meeting, Rome, Italy. Jun 11-13, 2015. (Poster Presentation)

Kelkar A, Cesta A, Li X, Bombardier C. Characterization of patient-reported pain medications in rheumatoid arthritis – Results from the Ontario Best Practices Research Initiative (OBRI). EULAR Annual Scientific Meeting, Rome, Italy. Jun 11-13, 2015. (Poster Presentation)

Tatangelo M, Tomlinson G, Kuriya B, Bombardier C. Disease activity patterns in rheumatoid arthritis in the first 3 years of follow up in usual care: Markov modelling shows rapid improvement in DAS28 states in 1st year followed by stable states in the last 2 years – Results from the Ontario Best Practices Research Initiative (OBRI). EULAR Annual Scientific Meeting, Rome, Italy. Jun 11-13, 2015. (Poster Presentation)

Widdifield J, Bernatsky S, Paterson M, Abrahamowicz M, Kuriya B, Tomlinson G, Tatangelo M, Thorne C, Pope J, Luo J, Bombardier C. Comparisons of reporting and level of agreement of co-morbidities ascertained from rheumatologists, patients, and health administrative data: A data linkage study among patients with rheumatoid arthritis.. EULAR Annual Scientific Meeting, Rome, Italy. Jun 11-13, 2015. (Poster Presentation)

CRA 2015:

Collins S, McKeown T, Heslegrave R, Bombardier C. Pilot evaluation of an electronic research platform supporting e-consent. CRA Annual Scientific Meeting, Quebec City, QC. Feb 4-7, 2015. (Poster Presentation)

Cui K, Jacob B, Widdifield J, Pope J, Li X, Kuriya B, Akhavan P, Bombardier C. Prevalence of Cardiovascular Disease and its Associations with Disease Severity in Rheumatoid Arthritis Patients – Data from the Ontario Best Practices Research Initiative (OBRI). CRA Annual Scientific Meeting, Quebec City, QC. Feb 4-7, 2015. (Poster Presentation)

Fullerton L, Cesta A, Hofstetter C, Bombardier C. Patient priorities in rheumatoid arthritis research – An exploration of patient perspectives from those enrolled in the Ontario Best Practices Research Initiative (OBRI) clinical registry. CRA Annual Scientific Meeting, Quebec City, QC. Feb 4-7, 2015. (Poster Presentation)

Gosio J, Bombardier C, Jacob B, Li X, Paterson M, Widdifield J. The generalizability of the Ontario Best Practices Research Initiative to the Ontario rheumatoid arthritis population and general population. CRA Annual Scientific Meeting, Quebec City, QC. Feb 4-7, 2015. (Poster Presentation)

Guo N, Jacob B, Li X, Couto S, Keystone E, Bombardier C. Disease activity in moderate rheumatoid arthritis patients – Results from the Ontario Best Practices Research Initiative. CRA Annual Scientific Meeting, Quebec City, QC. Feb 4-7, 2015. (Poster Presentation)

Harold A, Collins S, Bombardier C. Clinical rheumatology research in the digital age: Consent and governance challenges. CRA Annual Scientific Meeting, Quebec City, QC. Feb 4-7, 2015. (Poster Presentation)

Jacob B, Li X, Cesta A, Kuriya B, Keystone E, Bombardier C. Comparison of patient self-reported and physician reported rheumatoid arthritis medication use – Results from the Ontario Best Practices Research Initiative. CRA Annual Scientific Meeting, Quebec City, QC. Feb 4-7, 2015. (Poster Presentation)

Kelkar A, Li X, Cesta A, Bombardier C. Characterization of patient reported pain medication in rheumatoid arthritis patients – Results from the Ontario Best Practices Research Initiative (OBRI). CRA Annual Scientific Meeting, Quebec City, QC. Feb 4-7, 2015. (Poster Presentation)

Kuriya B, Li X, Jacob B, Widdifield J, Pope J, Bombardier C. Time-to-remission, time-to-relapse and disease severity at the time of relapse in RA – Results from the Ontario Best Practices Research Initiative. CRA Annual Scientific Meeting, Quebec City, QC. Feb 4-7, 2015. (Poster Presentation)

McKeown T, Jacob B, Li X, Couto S, Bensen W, Ahluwalia V, Karasik A, Bombardier C. Comparison of medication use in rheumatoid arthritis patients between university and community settings – Results from the Ontario Best Practices Research Initiative. CRA Annual Scientific Meeting, Quebec City, QC. Feb 4-7, 2015. (Poster Presentation)

Rohekar G, Jacob B, Pope J, Bombardier C. Durability of first biologic is not influenced by initial/early DAS28. CRA Annual Scientific Meeting, Quebec City, QC. Feb 4-7, 2015. (Poster Presentation)

Tatangelo M, Tomlinson G, Bombardier C. Derivation and comparison utility scores for economic evaluation in large datasets: Modeling patient level EQ-5D using the Ontario Best Practices Research Initiative. CRA Annual Scientific Meeting, Quebec City, QC. Feb 4-7, 2015. (Poster Presentation)

Tatangelo M, Li X, Cesta A, Paterson M, Widdifield J, Bombardier C. Harnessing the power of administrative data linkage: Results from the Ontario Best Practices Research Initiative clinical linked cohort. CRA Annual Scientific Meeting, Quebec City, QC. Feb 4-7, 2015. (Poster Presentation)

ACR 2014:

Cui K, Jacob B, Pope J, Widdifield J, Li X, Kuriya B, Akhavan P, Bombardier C. Characteristics of rheumatoid arthritis patients with and without cardiovascular diseases – Data from the Ontario Best Practices Research Initiative. ACR Annual Scientific Meeting, Boston, MA, Nov 14-19, 2014. (Poster Presentation)

Jacob B, Li X, Cesta A, Kuriya B, Keystone E, Bombardier C. Comparison of Patient Self-Reported and Physician Reported Rheumatoid Arthritis Medication Use – Results from the Ontario Best Practices Research Initiative. ACR Annual Scientific Meeting, Boston, MA, Nov 14-19, 2014. (Poster Presentation)

Kuriya B, Li X, Jacob B, Widdifield J, Pope J, Bombardier C. Time-to-remission, time-to-relapse in RA – Results from the Ontario Best Practice Research Initiative (OBRI). ACR Annual Scientific Meeting, Boston, MA, Nov 14-19, 2014. (Oral Presentation)

McKeown T, Jacob B, Li X, Couto S, Bensen W, Ahluwalia, Karasik A, Bombardier C. Comparison of medication use in rheumatoid arthritis patients between university and private settings – Results from the Ontario Best Practice Research Initiative. ACR Annual Scientific Meeting, Boston, MA, Nov 14-19, 2014. (Poster Presentation)

Rohekar G, Jacob B, Pope J, Bombardier C. Durability of first biologic is not influenced by initial/early DAS28. ACR Annual Scientific Meeting, Boston, MA, Nov 14-19, 2014. (Poster Presentation)

Widdifield J, Bombardier C, Thorne C, Jaakkimainen L, Paterson M, Bernatsky S, Young J, Wing L, Ivers N, Butt D, Poon V, Ahluwalia V, Tu K. A novel approach to assess wait times to rheumatologists. ACR Annual Scientific Meeting, Boston, MA, Nov 14-19, 2014. (Poster Presentation)

Widdifield J, Bombardier C, Young J, Ivers N, Jaakkimainen L, Bernatsky S, Paterson M, Thorne C, Akhavan P, Butt D, Ahluwalia V, Tu K. Quality of primary care management of patients with and without rheumatoid arthritis. ACR Annual Scientific Meeting, Boston, MA, Nov 14-19, 2014. (Oral Presentation)

TGRI 2014:

Cui K, Jacob B, Widdifield J, Pope J, Li X, Kuriya B, Akhavan P, Bombardier C. Prevalence and characteristics of cardiovascular diseases in rheumatoid arthritis patients – Data from the Ontario Best Practice Research Initiative. TGRI Annual Research Day, Oct. 2014, Toronto, ON. (Poster Presentation)

Gosio J, Bombardier C, Jacob B, Li X, Widdifield J. The generalizibility of the Ontario Best Practices Research Initiative to the Ontario rheumatoid arthritis population and general population. TGRI Annual Research Day, Oct. 2014, Toronto, ON. (Poster Presentation)

Guo N, Jacob B, Li X, Couto S, Keystone E, Bombardier C. Disease activity in moderate rheumatoid arthritis patients – Results from the Ontario Best Practices Research Initiative. TGRI Annual Research Day, Oct. 2014, Toronto, ON. (Poster Presentation)

McKeown T, Jacob B, Li X, Couto S, Bensen B, Ahuluwalia V, Karasik A, Bombardier C. Comparison of patients in different rheumatology settings – Results from the Ontario Best Practice Research Initiative. TGRI Annual Research Day, Oct. 2014, Toronto, ON. (Poster Presentation)

Tatangelo M, Tomlinson G, Bombardier C. Creation and comparison of a quality of life reference set using utility from a large observational cohort: Results from the Ontario Best Practices Research Initiative. TGRI Annual Research Day, Oct. 2014, Toronto, ON. (Poster Presentation)

EULAR 2014:

Mittoo S, Jacob B, Bombardier C. Lung disease among rheumatoid arthritis patients – Results from Ontario Biologics Research Initiative (OBRI). EULAR Scientific Meeting, Paris, France. June 11-14, 2014. (Poster Presentation)

Hazlewood G, Jacob B, Akhavan P, Bombardier C. Methotrexate parenteral administration versus oral delivery: A comparison of treatment survival using Ontario Best Practice Research Initiative (OBRI) cohort. EULAR Scientific Meeting, Paris, France. June 11-14, 2014. (Poster Presentation)

Jacob B, Tomlinson GA, Akhavan P, Bombardier C. Cigarette smoking and RA disease activity and health related QOL: Results from Ontario Best Practices Initiative. EULAR Scientific Meeting, Paris, France. June 11-14, 2014. (Poster Presentation)

Widdifield J, Young, Bombardier C, Jaakkimainen RL, Butt D, Ivers N, Bernatsky S, Paterson JM, Thorne C, Ahluwalia V, Tomlinson G, Tu K. Identifying Patients With Rheumatoid Arthritis in Primary Care Electronic Medical Records. EULAR Scientific Meeting, Paris, France. June 11-14, 2014. (Poster Presentation)

CAREB 2014:

Heslegrave R, Harold A, Knoppers BM, Zawati M, Bombardier C. Longitudinal Clinical Research in the Digital Age: Consent, Governance, and Ethics Challenges. Canadian Association of Research Ethics Boards (CAREB) 2014 Conference. Montreal, Quebec, April 25, 2014. (Oral Presentation)

CRA 2014:

Bombardier C, Heslegrave R, Collins S, Baron M, Zawati M, Taillefer S, Knoppers BM. Electronic Consent Processes for Rheumatology Research (11). Whistler, BC, Feb 26-Mar 1, 2014. (Poster Presentation)

Cesta A, Li X ,  Couto S, Jacob B, Bombardier C. Adherence to rheumatoid arthritis medications and the reasons for non-compliance: results from OBRI (147). Whistler, BC, Feb 26-Mar 1, 2014. (Poster Presentation)

Jacob B, Tomlinson GA, Akhavan P, Bombardier C. Cigarette smoking and disease activity in rheumatoid arthritis patients: Results from Ontario Best Practice Research Initiative (OBRI). Whistler, BC, Feb 26-Mar 1, 2014. (Poster Presentation)

Kelkar A, Couto S, Jacob B, Bombardier C. Use of MEDSCHECK program among RA patients – results from OBRI (148).Whistler, BC, Feb 26-Mar 1, 2014. (Poster Presentation)

Nguyen J, Jacob B, Akhavan P, Bombardier C. Methods used in standardizing drug names: experience from OBRI study (146). Whistler, BC, Feb 26-Mar 1, 2014. (Poster Presentation)

Tatangelo M and Bombardier C. Economic evaluation using observational data: A scoping review (187). Whistler, BC, Feb 26-Mar 1, 2014. (Poster Presentation)

Tatangelo M, Tomlinson G, Bombardier C. Mapping the Health Assessment Questionnaire on a preference based utility measure in a large Canadian rheumatoid arthritis cohort: Results from OBRI. Whistler, BC, Feb 26-Mar 1, 2014. (Poster Presentation)

ACR 2013:

Akhavan P, Jacob B, Keystone E, Li X, Thorne C and Bombardier C. Factors affecting the discrepancy between physician and patient global  assessment of disease activity in early and established rheumatoid arthritis  patients – Results from OBRI. San Diego, CA. October 25-30, 2013. (Poster Presentation)

Akhavan P, Jacob B, Fortin PR, Tomlinson GA and Bombardier C. Predictive validity of low disease activity using patient reported measures on long term outcomes in patients with early rheumatoid arthritis – results from Study of New Onset Rheumatoid Arthritis and OBRI. San Diego CA, October 25-30, 2013. (Oral Presentation)

Kuriya B, Jacob B, Widdifield J, Li X, Bombardier C. How often are core variables reported to calculate common Disease Activity Scores measured in routine care of rheumatoid arthritis patients? San Diego CA, October 25-30, 2013. (Poster Presentation)

Nadarajah T, Jacob B, Akhavan P, Kuriya B. Keystone E, Bombardier C. Does age at disease onset influence disease activity and function in rheumatoid arthritis patients? Results from the OBRI registry. San Diego, CA. October 25-30, 2013. (Oral Presentation)

Tatangelo M, Tomlinson G, and Bombardier C. Mapping the Health Assessment Questionnaire on a preference based utility measure in a large Canadian rheumatoid arthritis cohort: Results from OBRI. San Diego, CA. October 25-30, 2013. (Poster Presentation)

Widdifield J, Paterson JM, Bernatsky S, Kuriya B, Thorne C, Hollands S, Bombardier C. All-cause mortality for patients with Rheumatoid Arthritis (RA) in a universal public health care system: Results from the ORAD. San Diego, CA. October 25-30, 2013. (Oral Presentation)

TGRI 2013:

Tatangelo M, Tomlinson G, Bombardier C. Mapping the Health Assessment Questionnaire on a preference based utility measure in a large Canadian rheumatoid arthritis cohort: Results from the Ontario Best Practices Research Initiative. 2013 TGRI Annual Research Day, Toronto, ON.

CRA 2013:

Widdifield J, Paterson JM, Bernatsky S, Tu K, Thorne C, Ivers N, Jaakkimainen L, Ahluwalia V, Bombardier C. Epidemiology of Rheumatoid Arthritis in a universal public health care system: Results from the Ontario RA administrative database (ORAD) (11). Presented at the 2013 CRA Annual Scientific Meeting, Ottawa, ON. Feb 14-16th, 2013. (Oral Presentation)

ACR 2012:

Widdifield J, Paterson JM, Bernatsky S, Tu K, Thorne JC, Ivers N, Butt D. Potential barriers that limit timely access to rheumatologists among patients with early rheumatoid arthritis in a universal public health care system. ACR Annual Scientific Meeting 2012. (Oral presentation)

EULAR 2012:

Widdifield J, Paterson JM, Bernatsky S, Tu K, Thorne C, Ivers N, Butt D. Rheumatoid Arthritis (RA) care: Geographic disparities and impact of primary care physicians on access to rheumatologists. EULAR Annual Meeting, Berlin, June 6-9, 2012. (Poster Presentation)

CAPT 2011:

Bombardier C.  Biologic Agents – View on Benefit/Safety. (Oral Presentation)

CRA 2011:

Thorne C, Cividino A, Pope J, Bernatsky S, Li X, Ashoor H, Cesta A, Bombardier C. Disease activity in patients prescribed biologics in Ontario: Results from the Ontario Biologics Research Initiative (OBRI) cohort (p.133).  Canadian Rheumatology Association Annual Scientific Meeting, Cancun, February 11-15, 2011. (Poster Presentation)

Widdifield J, Bernatsky S, Paterson JM, Gunraj N, Thorne JC, Pope J, Cividino A, Bombardier C. Demyelinating events in seniors with Rheumatoid Arthritis (RA): A population-based study (p. 77). Canadian Rheumatology Association Annual Scientific Meeting, Cancun, February 11-15, 2011. (Poster Presentation)

Widdifield J, Bernatsky S, Paterson JM, Gunraj N, Thorne JC, Pope J, Cividino A, Bombardier C. The incidence of herpes zoster in seniors with rheumatoid arthritis: A population-based study (p. 78). Canadian Rheumatology Association Annual Scientific Meeting, Cancun, February 11-15, 2011. (Poster Presentation)

EULAR 2011:

Widdifield J, Bernatsky S, Paterson JM, Gunraj N, Cividino A, Thorne JC, Pope J, Bombardier C. Hospitalization for acute hepatotoxicity among seniors with rheumatoid arthritis. Ann Rheum Dis 2011;70(Suppl3):453. (Poster Presentation)

Widdifield J, Bernatsky S, Paterson JM, Gunraj N, Cividino A, Thorne JC, Pope J, Bombardier C. Use of non-steroidal anti-inflammatory drugs, selective cyclo-oxygenase inhibitors (coxibs), proton pump inhibitors and H2-receptor antagonists and risk of serious infections among seniors with rheumatoid arthritis. Ann Rheum Dis 2011;70(Suppl 3):453. (Poster Presentation)

ACR 2010:

Widdifield J, Bernatsky S, Paterson JM, Gunraj N, Pope J, Thorne C, Cividino A. Demyelinating events in seniors with rheumatoid arthritis. Arthritis Rheum 2010:62(Suppl). (Poster Presentation)

Widdifield J, Bernatsky S, Paterson JM, Pope JE, Thorne C, Cividino A. Invasive fungal infections in seniors with rheumatoid arthritis: A population-based study from the Ontario Biologics Research Initiative. Arthritis Rheum 2010: 62(Suppl); S313. (Poster Presentation)

Widdifield J, Bernatsky S, Paterson JM, Gunraj N, Pope JE, Thorne C, Cividino A. The incidence of herpes zoster in seniors with rheumatoid arthritis. Arthritis Rheum 2010: 62(Suppl); S341. (Poster presentation)

CADTH 2010:

Bernatsky S, Paterson M, Pope J, Widdifield J, Thorne JC, Cividino A, Bombardier C.  Under utilization of Disease Modifying Antirheumatic Drugs (Dmards) in Early Rheumatoid Arthritis (ERA): A population-based study from the Ontario Biologics Research Initiative. Comparing rheumatology care with primary care. Canadian Agency for Drugs and Technologies in Health. (Poster Presentation)

CAPT 2010:

Bernatsky S, Paterson M, Hux J, Thorne C, Cividino A, Pope J, Bombardier C. RA and risk of serious infections: A nested case-control study: Update from the OBRI administrative database analysis. (Poster Presentation)

Bernatsky S, Paterson M, Pope J, Widdifield J, Thorne C, Cividino A, Bombardier C. Under utilization of Disease Modifying Antirheumatic Drugs (Dmards) in Early Rheumatoid Arthritis (ERA): A population-based study from the Ontario Biologics Research Initiative. Comparing rheumatology care with primary care. Canadian Agency for Drugs and Technologies in Health. (Poster Presentation)

Bombardier C, Thorne C, Cividino A, Widdifield J, Pope J, Bernatsky S, Ashoor H, Cesta A, Li X, Paterson M. Baseline characteristics & preliminary efficacy results of patients receiving biologic and traditional DMARDs in Ontario. (Poster Presentation)

CRA 2010:

Bernatsky S, Paterson M, Pope J, Widdifield J, Thorne C, Cividino A, Bombardier C. Serious fungal infections in seniors with Rheumatoid Arthritis (RA): A population based study. Results of the OBRI administrative database analysis. J Rheumatol 2010; 37(6): 1279-79. (Poster Presentation)

Bernatsky S, Paterson M, Widdifield J, Thorne C, Pope J, Cividino A, Bombardier C. RA and risk of serious infections: A nested case-control study. Results from the Ontario Biologics Research Initiative (p. 14). J Rheumatol 2010; 37(6): 1279-79. (Poster Presentation)

Bernatsky S, Paterson M, Pope J, Widdifield J, Thorne C, Cividino A, Bombardier C. Under utilization of Dmards in early rheumatoid arthritis: A population-based study from the Ontario Biologics Research Initiative. Comparing Rheumatology Care With Primary Care (p. 228). J Rheumatol 2010; 37(6): 1348-48. (Poster Presentation)

Bombardier C, Thorne C, Cividino A, Widdifield J, Pope J, Bernatsky S, Ashoor H, Cesta A, Li X, Paterson M. Baseline characteristics and preliminary efficacy results of patients receiving biologic and traditional Disease Modifying Anti-Rheumatic Drugs (Dmards) in Ontario: Results From The OBRI (p.17). J Rheumatol 2010; 37(6): 1280-80. (Poster Presentation)

Pease C, Pope J, Truong D, Bombardier C, Widdifield J, Thorne C, Haraoui B, Psaradellis F, Sampalis J, Bonner A. Comparison Of Anti-TNF Treatment Initiation In RA Databases Demonstrates Wide Country Variability In Patient Parameters At Initiation Of Anti-TNF Therapy (p.90). J Rheumatol 2010; 37(6): 1304-04.

Widdifield J, Thorne C, Hofstetter C, Lyddiatt A, Pugh P, Frank P, Bombardier C. Elevating Patients’ Knowledge On The Process To Access Publicly Funded Biologic Therapies: Benefits Of Collaborative Research Efforts (p. 229). J Rheumatol 2010; 37(6): 1348-49. (Poster Presentation)

CRC 2010:

Bombardier C. The Ontario Biologics Research Initiative (OBRI): An innovative platform For real-world drug surveillance and evidence-based practice indicators. (Poster Presentation)

EULAR 2010:

Bernatsky S, Widdifield J, Paterson M, Pope J, Thorne C, Bombardier C. Complicated herpes zoster infections in seniors with RA. Ann Rheum Dis 2010; 69(S3):675. (Poster Presentation)

Bernatsky S, Paterson M, Widdifield J, Pope J, Thorne C, Cividino A, Bombardier C. Rheumatoid arthritis and risk of serious infections: A nested case-control study from the Ontario Biologics Research Initiative. Ann Rheum Dis 2010; 69(S3): 495. (Poster Presentation)

Bernatsky S, Paterson M, Pope J, Widdifield J, Thorne C, Cividino A, Bombardier C. Serious fungal infection in seniors with rheumatoid arthritis. Ann Rheum Dis 2010; 69(S3):675. (Poster Presentation)

Bernatsky S, Widdifield J, Paterson M, Cividino A, Pope J, Thorne C, Bombardier C. Under-utilization of DMARDS in seniors with early RA. Ann Rheum Dis 2010; 69(Suppl3):93. (Poster Presentation)

ACR 2009:

Bernatsky S, Paterson M, Thorne C, Cividino A, Pope J, Widdifield J, Bombardier C. Predictors of serious infections in seniors with Rheumatoid Arthritis (RA): Results of the OBRI administrative database analysis. Arthritis Rheum 2009;60 Suppl 10:720. (Poster Presentation)

CADTH 2009:

Bernatsky S, Bombardier C, Cividino A, Hux J, Paterson M, Pope J, Thorne JC. An evaluation of the potential effects of a national consensus statement on optimal treatment of early rheumatoid arthritis in Ontario. Canadian Agency for Drugs and Technologies in Health 2009 Symposium. (Poster Presentation)

CAPT 2009:

Bernatsky S, Paterson M, Bhamani A, Hux J, Cividino A, Pope J, Thorne JC, Bombardier C. Disease-Modifying Anti-Rheumatic Drug (DMARD) exposures and serious infections in seniors with Rheumatoid Arthritis (RA): A nested case-control study. Can J Clin Pharmacol 2009;16(1).

Bernatsky S, Bombardier C, Bhamani A, Cividino A, Hux J, Paterson M, Pope J, Thorne JC. Tuberculosis (TB) in a population-based cohort of seniors with Rheumatoid Arthritis (RA). Can J Clin Pharmacol 2009;16(1). (Poster Presentation)

Bernatsky S, Paterson M, Hux J, Cividino A, Pope J, Thorne JC, et al. Use of administrative data to determine the potential effects of a national consensus statement on optimal early Rheumatoid Arthritis (RA) treatment in persons >65. Can J Clin Pharmacol 2009;16(1).

Bernatsky S, Paterson M, Hux J, Cividino A, Pope J, Thorne JC, et al. Utilization of Biologic Response Modifying Drugs (BRMs) by Ontario rheumatology specialists. Can J Clin Pharmacol 2009;16(1). (Poster Presentation)

Bernatsky S, Bombardier C, Paterson JM, Hux J, Cividino A, Pope J, Thorne C. An evaluation of the potential effects of a national consensus statement on optimal treatment of early rheumatoid arthritis in Ontario. J Rheumatol 2009; 36(11): 2589-90.

Bernatsky S, Paterson JM, Bhamani A, Hux J, Cividino A, Bombardier C, Pope J, Thorne C. Medication exposures and serious infections in a population-based cohort of older individuals with Rheumatoid Arthritis (RA). J Rheumatol 2009; 36(11): 2590-90. (Poster Presentation)

Bernatsky S, Paterson M, Hux J, Cividino A, Thorne C, Bombardier C, Pope J. Serious infections in a population-based cohort of older individuals with rheumatoid arthritis. J Rheumatol 2009; 36(11): 2565-65. (Poster Presentation)

Bombardier C, Paterson JM, Zagorski B, Hux J, Bernatsky S, Cividino A, Pope J, Thorne C. Use of biologic response modifying drugs by Ontario rheumatology specialists: 2008 Update. J Rheumatol 2009; 36(11): 2590. (Poster Presentation)

Bombardier C, Bernatsky S, Cividino A, Paterson M, Pope J, Thorne C, Widdifield J, Li X. Baseline characteristics of patients receiving biologic and DMARD therapy in Ontario: Results From the Ontario Biologics Research Initiative. J Rheumatol 2009; 36(11): 2565-66. (Poster Presentation)

EULAR 2009:

Bernatsky S, Paterson M, Hux J, Cividino A, Pope J, Thorne JC, Bombardier C. An Evaluation of the Potential Effects of a National Consensus Statement on Optimal Treatment of Early Rheumatoid Arthritis in Ontario. Ann Rheum Dis 2009; 68(S3):549.

Bernatsky S, Paterson M, Hux J, Cividino A, Pope J, Thorne JC, Widdifield J, Bombardier C. Markers of Disease Activity and Corticosteroids Predict Serious Infection in Older Individuals With RA. Ann Rheum Dis 2009; 68(S3):132.

Bernatsky S, Paterson M, Hux J, Cividino A, Pope J, Thorne JC, Bombardier C. Tuberculosis In A Population-Based Cohort Of Seniors With RA. Ann Rheum Dis 2009; 68(S3):568.

Bombardier C, Bernatsky S, Paterson M, Hux J, Cividino A, Pope J, Thorne JC, Widdifield J. Baseline Characteristics Of Patients Receiving Biologic And DMARD Therapy In Ontario: Results From The Ontario Biologics Research Initiative. Ann Rheum Dis 2009; 68(S3); 233.

ACR 2008:

Bernatsky S, Paterson M, Hux J, Cividino A, Pope J, Thorne C, Bombardier C. Serious Infections In A Population-Based Cohort Of Older Individuals With Rheumatoid Arthritis. Arthritis and Rheumatism 2008; 58(9): S270-S270.

CRA 2008:

Bombardier C, Ciurea I, English J, Wilkins A. An innovative approach to practice based post-marketing surveillance of rheumatoid arthritis using an established patient surveillance system: Results of a feasibility study. J Rheumatol 2008; 35(6):1196-97.

Bombardier C, Ciurea I, English J, Wilkins A. Characteristics of patients with rheumatoid arthritis who are members of the medic alert system in Ontario. J Rheumatol 2008; 35(6):1197-97.

Bombardier C, English J, Thorne C, Cividino A, Pope J. A qualitative study to determine best methods for post-marketing surveillance in usual rheumatology care in Ontario. J Rheumatol 2008; 35(6):1199-99.